WHO's study finds 4 repurposed drugs that have no effect on COVID-19 mortality rate

interim results of a study conducted by WHO revealed conclusive evidence about ineffectiveness of Remdesivir, Hydroxychloroquine, Lopinavir/Ritonavir and Interferon for treatment of COVID-19. As per WHO's Solidarity rapeutics Trial,  repurposed drugs have little to effect on mortality rate among coronavirus patients. aim of this study was to find out effect of se drugs on mortality rate, initiation of ventilation and duration of hospital stay. This study includes participants from over 30 countries and is touted as ' world’s largest randomized control trial on COVID-19 rapeutics'. 

WHO study on repurposed drugs

Solidarity rapeutics Trials were undertaken by 405 hospitals in 30 countries and a total of 11,266 ults were randomized for study. A total of 2750 people were ministered Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon plus Lopinavir, 1412 only Interferon, and 4088 were given study drug. Following primary results, trials for Hydroxychloroquine and Lopinavir were discontinued as y did t show any benefits. results of study, which is currently under review for publication in a medical journal, are available on preprint server medRxiv. 

Re | WHO Says Safety 'primary Focus' After Johnson & Johnson Halts COVID-19 Vaccine Trials

" mortality findings contain most of randomized evidence on Remdesivir and Interferon and are consistent with meta-analyses of mortality in all major trials," re study.

Re | WHO Lauds India For Helping Myanmar With 3000 Vials Of Antiviral Drugs To Fight COVID-19

ICMR on WHO's Solidarity rapeutics Trial

Indian Council of Medical Research (ICMR) was an active partner in Solidarity rapeutics Trial conducted under guidance of World Health Organization. ICMR issued a statement after interim results from study were revealed by WHO. Calling it a 'well-coordinated national effort', ICMR hailed Dr Sheela Godbole who heed study led by ICMR-National AIDS Research Institute (NARI) of Pune. 

Re | WHO Says COVID-19 Puts Global Fight Against Tuberculosis At Risk, Calls For Urgent Action

As per statement, he of ICMR  Division of Epidemiology and Communicable Diseases Dr Samiran Panda said, " trial comprised 26 actively randomizing sites with 937 participants in India. We are grateful to trial participants and ir families for contributing to se crucial findings."

Re | WHO Chief Scientist Says Young People May Have To Wait For COVID-19 Vaccine Until 2022

official statement furr informed that aside from contributing one-tenth participants in WHO trial, ICMR also conducted a PLACID trial for convalescent plasma which showed benefit of it in COVID-19 treatment. 

Re | WHO Chief: COVID-19 Vaccine Will Be Allocated Based On ACT-Accelerator Principles

Re | WHO Backs Remdesivir Trial Data After Gile Terms It Inconsistent With 'robust Evidence'

(With inputs from ANI)